Following a reimbursement review the French Ministry of Health has published new final classifications and prices within Ostomy Care, Continence Care and Wound Care in France. The new classifications and prices will be implemented as of 1 July 2019 for Ostomy Care and Continence Care and have been implemented as of 1 June 2019 for Wound Care.
For Coloplast, the price reform represents an average reduction in prices in France for Ostomy Care and Continence Care of ~9% and Wound Care of ~2%.
For 2017/18, Coloplast reported revenues of around DKK 1.7bn in Ostomy Care and Continence Care in France.
Coloplast continues to analyse the final impact of the reform and will implement mitigating activities.
Coloplast’s full year financial guidance for 2018/19 is unchanged as a result of the price reform.
Coloplast will provide guidance for 2019/20 in connection with our FY 2018/19 results on 5 November 2019.
Coloplast’s long-term guidance financial guidance for the LEAD20 strategy period running until end 2019/20 is an annual organic growth of 7-9%, and an EBIT margin of more than 30% at constant exchange rates.
Coloplast A/S
For more information, please contact:
Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 / 4911 3376
E-mail dkebj@coloplast.com
Rasmus Sørensen
Senior Manager, Investor Relations
Tel. +45 4911 1800 / 4911 1786
E-mail dkraso@coloplast.com
Press and the media
Lina Danstrup
Senior Media Relations Manager, Corporate Communications
Tel. +45 4911 2607
E-mail dklina@coloplast.com
Attachment
